Buy Everecan : Everolimus 10 mg Tablets Online

Description

Introduction

Everecan, manufactured by Miracalus Pharma Pvt. Ltd., is a medication containing everolimus as its active substance. It belongs to the class of medications known as mammalian target of rapamycin (mTOR) inhibitors and is primarily used in the treatment of various types of cancer. This description provides an overview of Everecan, its characteristics, clinical applications, and considerations.

Characteristics

1. Active Substance: Everecan contains everolimus, a potent mTOR inhibitor that works by inhibiting the activity of the mammalian target of rapamycin (mTOR) kinase. mTOR plays a crucial role in cell growth, proliferation, and survival, and its dysregulation is commonly observed in cancer cells. By blocking mTOR signaling, everolimus helps suppress tumor growth and progression.
2. Formulation: Everecan is available in the form of tablets, with each tablet containing a specific dosage of everolimus (10 milligrams). The tablets are formulated for oral administration and are designed to provide a precise and standardized dosage of the active ingredient.

Clinical Applications

1. Cancer Treatment: Everecan is indicated for the treatment of various types of cancer, including advanced renal cell carcinoma (kidney cancer), metastatic breast cancer, neuroendocrine tumors of pancreatic origin, and advanced gastrointestinal or lung neuroendocrine tumors. It may be used alone or in combination with other anticancer therapies, such as hormonal therapy, chemotherapy, or targeted therapy.

Considerations

1. Dosage and Administration: The recommended dosage of Everecan may vary depending on the type of cancer being treated, the patient’s overall health status, and treatment response. It is typically administered orally once daily, at the same time each day, with or without food. Patients should swallow the tablets whole with a glass of water and avoid crushing or chewing them.
2. Monitoring: Regular monitoring of patients receiving Everecan therapy is essential to assess treatment response, detect potential adverse effects, and adjust the dosage as needed. This may include clinical evaluations, imaging studies, laboratory tests, and assessment of vital signs.
3. Adverse Effects: Common adverse effects associated with Everecan may include stomatitis (mouth sores), diarrhea, nausea, vomiting, fatigue, rash, and decreased appetite. These side effects are usually mild to moderate in severity and manageable with supportive care or dose adjustments. Patients should report any new or worsening symptoms to their healthcare provider.
4. Immunosuppression: Everolimus may cause immunosuppression, increasing the risk of infections and compromising immune function. Patients receiving Everecan therapy should be monitored for signs of infection, and appropriate prophylactic measures may be implemented to reduce the risk of opportunistic infections.
5. Contraindications: Everecan is contraindicated in individuals with a known hypersensitivity to everolimus or any of its components. It should not be used in patients with uncontrolled diabetes mellitus, severe hepatic impairment, or interstitial lung disease. Everecan should be used with caution in patients with impaired renal function or a history of immunosuppression.

Conclusion

Everecan, containing everolimus as its active substance, is a valuable medication for the treatment of various types of cancer. By inhibiting mTOR signaling, Everecan helps suppress tumor growth and improve treatment outcomes in patients with advanced or metastatic disease. However, its use requires careful consideration of dosage, monitoring, and potential adverse effects, and should be guided by a qualified healthcare provider to ensure safe and effective treatment outcomes. As with any medication, consultation with a healthcare provider is essential to determine the appropriate use of Everecan and minimize potential risks.